Clinical trial
Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule…
NCT00259753 · OPKO Health, Inc., Industry · Completed
Key facts
| NCT number | NCT00259753 |
|---|---|
| Title | Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration |
| Official title | A Phase II, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration |
| Lead sponsor | OPKO Health, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Drug |
| Interventions | Bevasiranib |
| Enrollment | 120 |
| Start date | Jul 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Dec 1, 2005 |
| Last update posted | Aug 5, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: